Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-08656795 (MET-815i) is an investigational biologic agent developed by Pfizer for chronic weight management. It functions as an agonist of the GDNF family receptor alpha-like (GFRAL), which is the high-affinity receptor for Growth Differentiation Factor 15 (GDF15). By activating the GFRAL-RET signaling complex in the hindbrain, specifically within the area postrema and nucleus of the solitary tract, the drug is intended to reduce food intake and promote weight loss. PF-08656795 is engineered as a long-acting therapy to allow for infrequent dosing. It is currently in Phase 1 clinical development to evaluate its safety, tolerability, and pharmacokinetics in individuals with obesity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PF-08656795.